跳至主要内容
临床试验/NCT00823082
NCT00823082已完成2 期

A Prospective Randomized Pilot Study to Evaluate the Effect of Preoperative Antithrombin Supplementation on Postoperative Levels of Antithrombin in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

Instituto Grifols, S.A.1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2009年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
200
试验地点
1
主要终点
Postoperative ATIII Levels at the ICU Admission

研究概览

简要总结

The purpose of this trial is to study the effects of preoperative antithrombin supplementation in patients undergoing cardiac surgery with cardiopulmonary bypass in order to maintain antithrombin levels in a range greater than 58% of functional activity and, eventually, to decrease negative clinical outcomes during the ICU stay.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female
  • At least 18 years of age
  • Subject needed elective cardiac surgery with cardiopulmonary bypass except for heart transplantation
  • Subject had a baseline ATIII level of less than 100% and equal to or above 60%
  • Subject signed the informed consent form
  • Subject was willing to comply with all aspects of the protocol, including blood sampling, for the total duration of the study

排除标准

  • Documented congenital ATIII deficiency or ATIII levels below 60%
  • Subject had a baseline ATIII level of 100% or higher
  • Subject needed emergency (non-elective) surgery
  • Subject needed heart transplantation
  • History of anaphylactic reaction(s) to blood or blood components
  • Allergies to excipients
  • Subject was pregnant
  • Subject had any medical condition that according to the investigators judgment worsens the surgical outcome above the expected
  • Subject had any medical condition which is likely to interfere with the evaluation of the study treatment and/or the satisfactory conduct of the trial according to the investigators judgment
  • Subject had participated in any another investigational study within the last 30 days previous to the inclusion

研究组 & 干预措施

Antithrombin III treatment group

Experimental

Preoperative ATIII supplementation administered immediately after anesthesia induction

干预措施: Antithrombin III (Drug)

结局指标

主要结局

Postoperative ATIII Levels at the ICU Admission

时间窗: ICU admission

Measurement of postoperative ATIII functional activity at ICU admission

Percentage of Subjects With ATIII Levels of 58% or Higher at ICU Admission

时间窗: ICU admission

Percentage of subjects with ATIII levels of 58% functional activity or higher at ICU admission

次要结局

  • Percentage of Subjects With Postoperative Myocardial Infarction(During ICU stay (maximum 70 days))
  • Percentage of Subjects With Adverse Neurologic Outcome(During ICU stay (maximum 70 days))
  • Percentage of Patients With Thromboembolic Events(During ICU stay (maximum 70 days))
  • ICU Stay Duration(During ICU stay (maximum 70 days))
  • In-hospital Postoperative Mortality(70 days after ICU admission (maximum))
  • Heparin Resistance(Immediately after anesthesia induction)
  • Postoperative Blood Loss in First 12 Hours(ICU admission through 12 hours post-operative)
  • Need for Blood Products(During ICU stay (maximum 70 days))
  • Percentage of Subjects Needing Surgical Re-exploration(During ICU stay (maximum 70 days))
  • Percentage of Subjects With Low Cardiac Syndrome(During ICU stay (maximum 70 days))
  • Percentage of Subjects With Renal Dysfunction(During ICU stay (maximum 70 days))
  • Mechanical Ventilation Duration(During ICU stay (maximum 70 days))
  • Length of Hospital Stay(During ICU stay (maximum 70 days))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验